Abstract: While the requested research direction is neurodegenerative disease, the provided literature exclusively evaluates the small-molecule compound Torin 1 (also referred to as TOR) within the context of oncology, specifically triple-negative breast cancer (TNBC). Torin 1 is identified as a potent inhibitor of the mammalian target of rapamycin (mTOR). This review synthesizes the available data on Torin 1 based strictly on the provided text, focusing on its pharmacological ability to trigger regulated cell death (RCD) subroutines, including autophagy-dependent cell death and apoptosis. Notably, the literature highlights the synergistic efficacy of Torin 1 when used in combination therapies, such as with chloroquine, to overcome tumor resistance and enhance therapeutic outcomes in specific TNBC subtypes.
1. Introduction
Triple-negative breast cancer (TNBC) is a highly aggressive cancer subtype characterized by the absence of hormone receptors and HER2, making it unresponsive to traditional hormone therapies and necessitating the discovery of novel targeted small-molecule compounds [1]. Regulated cell death (RCD), which encompasses subroutines like apoptosis, autophagy-dependent cell death, necroptosis, and mitotic catastrophe, has emerged as a critical target for these therapies [1]. Torin 1 is a small-molecule mTOR inhibitor that has demonstrated significant potential in modulating these RCD pathways to combat TNBC [1].
2. Pharmacological Activity
Torin 1 exhibits its primary pharmacological activity by modulating autophagy and apoptosis in cancer cells. Because the monotherapy of small-molecule drugs often faces efficacy challenges, Torin 1 has been prominently investigated as part of a combination therapy [1]. Specifically, the combined application of Torin 1 and chloroquine (CQ), a Toll-like receptor (TLR) inhibitor, has been shown to achieve a half-lethal effect in TNBC models [1]. This combination actively induces both autophagic cell death and apoptotic cell death, showing particular efficacy in the Basal-like 2 (BL2) subtype of TNBC [1].
3. Molecular Mechanism of Action
The molecular mechanism of Torin 1 is rooted in its function as an inhibitor of the mammalian target of rapamycin (mTOR) [1]. mTOR is a central negative regulator of autophagy, existing in two complexes: mTORC1 and mTORC2 [1]. Under normal conditions, the PI3KC1-Akt-mTORC1 signaling pathway inhibits the occurrence of autophagy to maintain cellular homeostasis [1]. By inhibiting mTOR, Torin 1 relieves this suppression. The inhibition of mTORC1 indirectly activates the unc-51-like kinase 1 (ULK1) complex (which includes ULK1, ATG101, ATG13, and FIP200) [1]. The activation of the ULK1 complex promotes the binding of Beclin1 to vacuolar protein sorting 34 (VPS34), ultimately driving the formation of autophagosomes and triggering autophagy-dependent cell death alongside apoptosis [1].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific atomic structure-activity relationship (SAR) of Torin 1, it highlights the broader class of mTOR inhibitors and their structural analogues. For instance, Torin 2, a chemical analogue of Torin 1, demonstrates that dual inhibition of mTOR and other PI3K-like kinases (PIKKs) leads to the accumulation of single-stranded DNA and replication disaster [1]. This structural targeting of both mTOR and PIKKs by Torin analogues is crucial for inducing mitotic catastrophe and subsequent death in TNBC tumor cells, suggesting that the core pharmacophore of Torin compounds is highly effective at disrupting kinase-dependent cell survival [1].
5. Current Limitations
A primary limitation of using small-molecule mTOR inhibitors like Torin 1 as monotherapies is the rapid emergence of drug-resistant mutations and the potential for multidrug resistance sites to appear [1]. Furthermore, autophagy acts as a "double-edged sword" in cancer; while it can promote cell death, cytoprotective autophagy can also provide energy and nutrients that help tumor cells survive adverse stimulation [1]. If not used in standardized combination regimens, the side effects of these drugs can increase, lowering patient tolerance and resulting in poor therapeutic efficacy [1].
6. Future Perspectives
The future development of Torin 1 and similar mTOR inhibitors relies heavily on rational combination therapies to maximize efficacy and minimize resistance. Combining Torin 1 with other agents, such as chloroquine, represents a highly promising strategy to synergistically activate multiple RCD subroutines (e.g., apoptosis and autophagy) [1]. Further research into the precise molecular characteristics of TNBC subtypes (such as the BL2 subtype targeted by Torin 1 combinations) will enable more accurate, individualized therapeutic strategies, ultimately improving the clinical prognosis for patients [1].
